TBX21 and relapsing-remitting multiple sclerosis: The analysis also revealed an increase in both transcription factors (double-positive CD3+TBet+RORγt+ cells) at day 14 for HC (p=0.0015) as well as for RRMS patients (p= 0.0004) (Figure 6F).